Pakistan Healthcare Solutions Conference in Doha fosters bilateral collaboration
Tribune News Network
Doha
The Embassy of Pakistan in Qatar, in collaboration with Hamad Medical Corporation's (HMC) ITQAN Clinical Simulation and Innovation Centre, successfully hosted the Pakistan Healthcare Solutions Conference on June 2, at the ITQAN Clinical Simulation and Innovation Centre in Doha. The event, organised with the Atlantic International Business Network (AIBN) as the executive partner, aimed to advance a shared vision for healthcare innovation and strengthen Pakistan-Qatar collaboration.
The conference was honoured by the presence of Federal Minister for National Health Services, Regulations and Coordination of Pakistan, Syed Mustafa Kamal, as the chief guest from Pakistan, and Assistant Minister for Health Affairs, Ministry of Public Health, Qatar, HE Dr. Salih Al Marri, as the chief guest from Qatar. Ali Al Janahi, HMC acting assistant managing director, Dr. Abdulla Ali Al-Ansari, medical advisor to the managing director of HMC, also attended, highlighting the high-level commitment to bilateral healthcare ties.
The event brought together key stakeholders from the medical, pharmaceutical, telehealth, academic, and regulatory sectors of both nations. It provided a platform for government officials, healthcare leaders, innovators, and investors to explore opportunities for cross-border partnerships and advancements in healthcare development.
The program commenced with inaugural addresses by Dean of Weill Cornell Medicine-Qatar, Javaid I. Sheikh, M.D., M.B.A., and the Executive Director of the ITQAN Clinical Simulation and Innovation Centre, Dr. Abdulla Ahmad. Their remarks underscored the transformative potential of collaborative efforts in strengthening healthcare systems between Pakistan and Qatar.
Keynote presentations were delivered by Lt. Gen. Arshad Naseem HI (M), surgeon general of Pakistan, and Prof. Dr. Ambreen Afzal Ehsan, vice president of the College of Physicians and Surgeons Pakistan. These sessions highlighted Pakistan's advancements in healthcare and set the stage for discussions on bilateral cooperation.
Two high-level panel discussions enriched the conference. The first, on Pakistan-Qatar R&D Collaboration, moderated by Rahid Mazhar, featured experts including Prof. Dr. Muhammad Yar, Dr. Ali Raza, Dr. Rayaz Malik, and Dr. Yousuf Al Maslamani. The second, on Emerging Smart Healthcare and Innovation Opportunities, moderated by Dr. Hasham Khan, included Dr. Fatih Mehmet Gul, Dr. Rola Hammoud, Dr. Zahid Ali, Dr. Javaid Sheikh, and Muhammad Irfan, focusing on innovative healthcare technologies.
Additional presentations were delivered by Dr. Obaidullah Malik, CEO of the Drug Regulatory Authority of Pakistan (DRAP); Amr Metwally, assistant executive director at ITQAN; Ikram Ul Haq, president of the Sialkot Chamber of Commerce; Muhammad Irfan, CEO of Xeven Solutions; and Tanvir Khan, representing Labware Arabia. These talks showcased innovations in regulatory frameworks, medical technology, and industry partnerships.
An exhibition featured stalls from leading companies such as Allison, Labware, and others, displaying advancements in medical devices, laboratory technologies, and AI-powered solutions. This interactive platform facilitated knowledge exchange and explored potential avenues for future collaboration.
The conference concluded with remarks by Hafiz Muhammad Talha, CEO of AIBN and managing director of Metas Qatar, followed by a closing address by Ambassador of Pakistan to Qatar HE Muhammad Aamer. The ambassador reaffirmed the Embassy's commitment to fostering enduring healthcare partnerships between Pakistan and Qatar.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
14 hours ago
- Qatar Tribune
QU celebrates first PhD graduates of its Health Sciences programme
Tribune News Network Doha Qatar University (QU) has announced the graduation of the first two students from its PhD in Health Sciences programme, marking a significant milestone for QU Health and its commitment to advancing research aligned with Qatar's national health priorities. The PhD in Health Sciences, governed by the 'Health Sector Graduate Studies Office', offers two specialised tracks: Biomedical and Pharmaceutical Research and Clinical and Population Health Research. This year's achievement highlights the graduation of one student from each track, signaling the program's growing impact on national and global health research. Dr. Jazeel Abdulmajeed is the first graduate of the Clinical and Population Health Research track. His research addressed the appropriate use of effect measures in clinical research, proposing improvements that enhance the interpretation and reliability of healthcare evidence, particularly in observational studies and meta-analyses. Dr. Abdulmajeed said, 'My PhD aimed to improve the methodological foundations of clinical research to ensure that health decisions are based on accurate and meaningful evidence. I am honoured to be the first graduate of this track and proud to contribute to the advancement of research excellence at QU.' Dr. Abdulmajeed was supervised by Prof. Suhail Doi, head of the Department of Population Medicine at the College of Medicine. Prof. Doi said, 'Dr. Abdulmajeed's research offers important methodological solutions that improve how we assess and apply healthcare data in real-world settings.' In parallel with his academic work, Dr. Abdulmajeed also contributes to the Business and Health Intelligence Department at the Primary Health Care Corporation and has served in various roles at the Ministry of Public Health. On her part, Nadin Younes, the first graduate of the Biomedical and Pharmaceutical Research track, focused her doctoral work on improving disease diagnostics. Her research led to the development of rapid, cost-effective tools to detect Norovirus and Hepatitis E Virus — pathogens that pose a high risk in densely populated and resource-limited environments. 'I aimed to design accessible and affordable diagnostic tools that could support early detection and better outbreak control,' Younes explained. 'I'm thankful to my supervisor and the supportive research environment at QU Health that made this possible.' Supervised by Prof. Gheyath Nasrallah, professor of Immunology and Microbiology at the College of Health Sciences, her work resulted in the creation of a novel lateral flow assay for Norovirus, which is now undergoing regulatory review with support for potential commercialisation. A complementary test for Hepatitis E Virus is also nearing completion. 'Nadin's research addresses a pressing public health need and demonstrates the potential of applied biomedical innovation in Qatar,' said Prof. Nasrallah. Dr. Muhammad Abdul Hadi, coordinator of the Clinical and Population Health Research track, emphasised the broader importance of this achievement, 'This graduation signifies more than academic success — it reflects our programme's vision of developing researchers who are equipped to address complex health challenges. We are proud of our graduates for setting a strong precedent for future cohorts,' Abdul Hadi said. Dr. Asad Javaid, coordinator of the Pharmaceutical and Biomedical Research track, also praised the significance of this achievement, saying, 'The success of our first graduate is a powerful testament to the relevance and innovation embedded in our curriculum. This programme is designed to empower researchers to translate scientific discovery into practical solutions that address real-world health challenges. Nadin's achievement is just the beginning of the impact we aim to deliver—both in Qatar and beyond.' With this milestone, QU continues to expand its role as a leader in health research and innovation, contributing to the nation's long-term goals under Qatar National Vision 2030.
Qatar Tribune
2 days ago
- Qatar Tribune
Pakistan Healthcare Solutions Conference in Doha fosters bilateral collaboration
Tribune News Network Doha The Embassy of Pakistan in Qatar, in collaboration with Hamad Medical Corporation's (HMC) ITQAN Clinical Simulation and Innovation Centre, successfully hosted the Pakistan Healthcare Solutions Conference on June 2, at the ITQAN Clinical Simulation and Innovation Centre in Doha. The event, organised with the Atlantic International Business Network (AIBN) as the executive partner, aimed to advance a shared vision for healthcare innovation and strengthen Pakistan-Qatar collaboration. The conference was honoured by the presence of Federal Minister for National Health Services, Regulations and Coordination of Pakistan, Syed Mustafa Kamal, as the chief guest from Pakistan, and Assistant Minister for Health Affairs, Ministry of Public Health, Qatar, HE Dr. Salih Al Marri, as the chief guest from Qatar. Ali Al Janahi, HMC acting assistant managing director, Dr. Abdulla Ali Al-Ansari, medical advisor to the managing director of HMC, also attended, highlighting the high-level commitment to bilateral healthcare ties. The event brought together key stakeholders from the medical, pharmaceutical, telehealth, academic, and regulatory sectors of both nations. It provided a platform for government officials, healthcare leaders, innovators, and investors to explore opportunities for cross-border partnerships and advancements in healthcare development. The program commenced with inaugural addresses by Dean of Weill Cornell Medicine-Qatar, Javaid I. Sheikh, M.D., M.B.A., and the Executive Director of the ITQAN Clinical Simulation and Innovation Centre, Dr. Abdulla Ahmad. Their remarks underscored the transformative potential of collaborative efforts in strengthening healthcare systems between Pakistan and Qatar. Keynote presentations were delivered by Lt. Gen. Arshad Naseem HI (M), surgeon general of Pakistan, and Prof. Dr. Ambreen Afzal Ehsan, vice president of the College of Physicians and Surgeons Pakistan. These sessions highlighted Pakistan's advancements in healthcare and set the stage for discussions on bilateral cooperation. Two high-level panel discussions enriched the conference. The first, on Pakistan-Qatar R&D Collaboration, moderated by Rahid Mazhar, featured experts including Prof. Dr. Muhammad Yar, Dr. Ali Raza, Dr. Rayaz Malik, and Dr. Yousuf Al Maslamani. The second, on Emerging Smart Healthcare and Innovation Opportunities, moderated by Dr. Hasham Khan, included Dr. Fatih Mehmet Gul, Dr. Rola Hammoud, Dr. Zahid Ali, Dr. Javaid Sheikh, and Muhammad Irfan, focusing on innovative healthcare technologies. Additional presentations were delivered by Dr. Obaidullah Malik, CEO of the Drug Regulatory Authority of Pakistan (DRAP); Amr Metwally, assistant executive director at ITQAN; Ikram Ul Haq, president of the Sialkot Chamber of Commerce; Muhammad Irfan, CEO of Xeven Solutions; and Tanvir Khan, representing Labware Arabia. These talks showcased innovations in regulatory frameworks, medical technology, and industry partnerships. An exhibition featured stalls from leading companies such as Allison, Labware, and others, displaying advancements in medical devices, laboratory technologies, and AI-powered solutions. This interactive platform facilitated knowledge exchange and explored potential avenues for future collaboration. The conference concluded with remarks by Hafiz Muhammad Talha, CEO of AIBN and managing director of Metas Qatar, followed by a closing address by Ambassador of Pakistan to Qatar HE Muhammad Aamer. The ambassador reaffirmed the Embassy's commitment to fostering enduring healthcare partnerships between Pakistan and Qatar.
Qatar Tribune
3 days ago
- Qatar Tribune
Sheikha Moza opens HSCT ward at Sidra Medicine
Tribune News Network Doha HH Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development, officially inaugurated the new paediatric Hematopoietic Stem Cell Transplant (HSCT) ward at Sidra Medicine, a Qatar Foundation entity. The new ward is dedicated to treating children with blood disorders, immune system diseases, and genetic conditions. During the visit, Sheikha Mozatoured the facility, engaged with clinical teams, and received an overview of the HSCT programme's role in advancing care and stem cell and gene therapies for children in Qatar and the region. Sheikha Moza was accompanied by Minister of Public Health HE Mansoor bin Ebrahim bin Saad Al Mahmoud, members of Sidra Medicine's Board of Directors and senior leadership, including Dr Iyabo Tinubu-Karch, Chief Executive Officer and Prof Ibrahim Janahi, Chief Medical Officer. The HSCT ward is a core part of Sidra Medicine's HSCT Programme, using curative therapies to provide life-saving care and treatment for children with a range of blood diseases and cancers. This includes malignant and non-malignant conditions such as leukemia, lymphoma, thalassemia, sickle cell disease, immune deficiencies, and metabolic disorders. HSCT also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new pediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections - one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
